arrow_back Civic Audit
Share share

US Support for Global Alzheimer's Fight

This act authorizes the United States to participate in and contribute to the Davos Alzheimer’s Collaborative (DAC). The goal is to accelerate research, diagnosis, and treatment of Alzheimer's disease globally, especially in lower-income countries where the problem is growing fastest. This means citizens in the US and other countries can expect faster access to new treatments and better care.
Key points
The US will join a global research and treatment initiative for Alzheimer's disease.
US financial support will be contingent on securing funds from other sources, not exceeding 33% of total contributions.
The aim is to develop diagnostics and treatments for diverse populations worldwide, including in the US.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 118_HR_10175
Sponsor: Rep. Bera, Ami [D-CA-6]
Process start date: 2024-11-20
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Global Alzheimer’s Initiative Now Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_10175.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-11-20.

What are the main provisions?

Key points include:

  • The US will join a global research and treatment initiative for Alzheimer's disease.
  • US financial support will be contingent on securing funds from other sources, not exceeding 33% of total contributions.
  • The aim is to develop diagnostics and treatments for diverse populations worldwide, including in the US.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Bera, Ami [D-CA-6].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Foreign Affairs.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

What is the impact of this bill?

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health